Core Insights - Delcath Systems, Inc. (DCTH) reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.13, and an improvement from a loss of $0.61 per share a year ago, indicating a 76.92% earnings surprise [1] - The company achieved revenues of $11.2 million for the quarter ended September 2024, aligning with the Zacks Consensus Estimate and showing a substantial increase from $0.43 million in the same quarter last year [2] - Delcath Systems shares have increased approximately 163% year-to-date, outperforming the S&P 500's gain of 25.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.16 on projected revenues of $11.35 million, while for the current fiscal year, the estimate is -$1.64 on revenues of $33.45 million [7] - The estimate revisions trend for Delcath Systems is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Stereotaxis Inc. (STXS), is expected to report a quarterly loss of $0.05 per share, reflecting a year-over-year change of +28.6%, with revenues anticipated to be $6.8 million, down 12.8% from the previous year [9][10]
Delcath Systems, Inc. (DCTH) Reports Q3 Loss